summari report ep beat
consensu estim ep beat rel
vs estim lower tax rate vs
estim partli off-set higher opex vs
estim revenu underli ex-fx
divestitur ahead estim consensu
 revenu underli came
estim non develop market revenu
underli miss estim emerg
market revenu underli beat forecast
ex-fx ep growth guidanc organ revenu
growth outlook rais top bottom line result
strong oper leverag bp ex-fx
bp guidanc
vascular group sale ex-fx beat
consensu in-lin estim cardiac rhythm
 heart failur sale ex-fx exceed consensu
estim coronari structur heart
sale ex-fx beat consensu
miss estim aortic peripher revenu
ex-fx consensu
estim minim invas therapi group revenu
grew underli beat consensu
forecast restor therapi group sale increas
ex-fx ahead consensu forecast
diabet revenu rose ex-fx better
consensu estim
growth guidanc estim
also increas ex-fx ep growth guidanc
ep guidanc unchang
outlook bracket consensu estim
earn call start et dial-in
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
quarter sum full-year total estim yet
adjust effect result
compani prioriti stock list
compani data secur llc estim reuter
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
